Search Videos by Topic or Participant
Browse by Series:

Personalized Medicine in Triple-Negative Breast Cancer

Panelists: Adam M. Brufsky, MD, PhD, University of Pittsburgh; Sara Hurvitz, MD, UCLA;Joyce A. O'Shaughnessy, MD, US Oncology; Edith A. Perez, MD,
Published Online: Wednesday, Oct 02, 2013
For High-Definition, Click
The area of precision medicine and personalized care has gained a great deal of attention in recent years, explains Adam M. Brufsky, MD, PhD. However, at this point, personalized treatment approaches for patients with triple-negative breast cancer (TNBC) remains an unmet need.

To help address this, assays such as the homologous recombination deficiency (HRD) score are currently under investigation, suggests Joyce A. O'Shaughnessy, MD. The HRD score is based on loss of heterozygosity (LOH) and may predict pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer, O'Shaughnessy notes.

Alterations in the BRCA1/ 2 genes represent a known actionable mutation in TNBC, points out Sara Hurvitz, MD. To capitalize on these mutations, clinical trials are exploring PARP inhibition. One such agent, BMN 673, demonstrated promising results in early phase clinical trials, Hurvitz notes.

Outside of molecularly targeted agents, research is examining the continued use of cytotoxics in TNBC, explains Hope S. Rugo, MD. In the randomized phase III CALGB 40502 trial, weekly paclitaxel was compared to weekly high-dose nab-paclitaxel or ixabepilone with or without bevacizumab as first-line therapy for metastatic breast cancer with subset analysis specifically in TNBC. Results from this subset analysis sparked further ongoing research into nab-paclitaxel specifically in patients with TNBC, Rugo suggests.
For High-Definition, Click
The area of precision medicine and personalized care has gained a great deal of attention in recent years, explains Adam M. Brufsky, MD, PhD. However, at this point, personalized treatment approaches for patients with triple-negative breast cancer (TNBC) remains an unmet need.

To help address this, assays such as the homologous recombination deficiency (HRD) score are currently under investigation, suggests Joyce A. O'Shaughnessy, MD. The HRD score is based on loss of heterozygosity (LOH) and may predict pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer, O'Shaughnessy notes.

Alterations in the BRCA1/ 2 genes represent a known actionable mutation in TNBC, points out Sara Hurvitz, MD. To capitalize on these mutations, clinical trials are exploring PARP inhibition. One such agent, BMN 673, demonstrated promising results in early phase clinical trials, Hurvitz notes.

Outside of molecularly targeted agents, research is examining the continued use of cytotoxics in TNBC, explains Hope S. Rugo, MD. In the randomized phase III CALGB 40502 trial, weekly paclitaxel was compared to weekly high-dose nab-paclitaxel or ixabepilone with or without bevacizumab as first-line therapy for metastatic breast cancer with subset analysis specifically in TNBC. Results from this subset analysis sparked further ongoing research into nab-paclitaxel specifically in patients with TNBC, Rugo suggests.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Consultations®: Integrating Molecular Testing into the Breast Cancer Treatment ParadigmSep 28, 20162.0
Community Practice Connections™: 14th Annual International Congress on the Future of Breast Cancer®Oct 01, 20162.0